A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results

High-dose rituximab (HD-R) combined with carmustine, cytarabine, etoposide, and melphalan (BEAM) and autologous stem cell transplant (ASCT) was effective and tolerable in a single-arm prospective study of relapsed aggressive B-cell non-Hodgkin’s lymphoma (R-NHL). We performed a randomized phase 2 st...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Haematol
Main Authors: Srour, Samer A., Li, Shaoying, Popat, Uday R., Qazilbash, Muzaffar H., Lozano-Cerrada, Sara, Maadani, Farzeneh, Alousi, Amin, Kebriaei, Partow, Anderlini, Paolo, Nieto, Yago, Jones, Roy, Shpall, Elizabeth, Champlin, Richard E., Hosing, Chitra
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5672904/
https://ncbi.nlm.nih.gov/pubmed/28485023
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14731
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados